EGFR and non-small cell lung carcinoma: Several studies have shown that although the initial response of EGFR-TKIs to 19DEL NSCLC patients and L858R is similar, the mPFS and mOS of 19DEL patients are significantly higher than those of L858R patients (38–40), and this difference may be attributed to the resistance mechanism.